Tibaldi Joseph
a Department of Medicine, Flushing Hospital Medical Center, 59-45 161st Street, Flushing, NY 11365, USA.
Expert Rev Endocrinol Metab. 2008 Mar;3(2):147-159. doi: 10.1586/17446651.3.2.147.
Type 2 diabetes mellitus (T2DM) is a complex disease characterized by insulin resistance and a progressive decline in β-cell function and mass. Current evidence suggests that β-cell dysfunction is present early in the course of the disease and that this dysfunction, rather than insulin resistance, is primarily responsible for the progression of T2DM. β-cell dysfunction can be accelerated by glucose toxicity, lipotoxicity, oxidative stress, chronic increases in inflammatory mediators and, potentially, the use of sulfonylureas. This review suggests that future efforts to limit the impact of T2DM must focus on strategies to preserve β-cell function. Several interventions have shown promise in this regard, including lifestyle modifications, thiazolidinediones, potassium channel openers, incretin mimetics, cytokine antagonists, bariatric surgery and dipeptidyl peptidase IV inhibitors, although therapeutic insulin remains the most robust and physiological approach.
2型糖尿病(T2DM)是一种复杂的疾病,其特征为胰岛素抵抗以及β细胞功能和数量的逐渐下降。目前的证据表明,β细胞功能障碍在疾病进程早期就已出现,并且这种功能障碍而非胰岛素抵抗是T2DM进展的主要原因。葡萄糖毒性、脂毒性、氧化应激、炎症介质的慢性增加以及潜在的磺脲类药物使用均可加速β细胞功能障碍。本综述表明,未来限制T2DM影响的努力必须集中在保护β细胞功能的策略上。在这方面,几种干预措施已显示出前景,包括生活方式改变、噻唑烷二酮类药物、钾通道开放剂、肠促胰岛素类似物、细胞因子拮抗剂、减肥手术和二肽基肽酶IV抑制剂,尽管治疗性胰岛素仍然是最有效且符合生理的方法。